Correlation Between Allarity Therapeutics and InMed Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Allarity Therapeutics and InMed Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Allarity Therapeutics and InMed Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Allarity Therapeutics and InMed Pharmaceuticals, you can compare the effects of market volatilities on Allarity Therapeutics and InMed Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Allarity Therapeutics with a short position of InMed Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Allarity Therapeutics and InMed Pharmaceuticals.

Diversification Opportunities for Allarity Therapeutics and InMed Pharmaceuticals

0.55
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Allarity and InMed is 0.55. Overlapping area represents the amount of risk that can be diversified away by holding Allarity Therapeutics and InMed Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on InMed Pharmaceuticals and Allarity Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Allarity Therapeutics are associated (or correlated) with InMed Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of InMed Pharmaceuticals has no effect on the direction of Allarity Therapeutics i.e., Allarity Therapeutics and InMed Pharmaceuticals go up and down completely randomly.

Pair Corralation between Allarity Therapeutics and InMed Pharmaceuticals

Given the investment horizon of 90 days Allarity Therapeutics is expected to under-perform the InMed Pharmaceuticals. In addition to that, Allarity Therapeutics is 1.08 times more volatile than InMed Pharmaceuticals. It trades about -0.29 of its total potential returns per unit of risk. InMed Pharmaceuticals is currently generating about -0.06 per unit of volatility. If you would invest  628.00  in InMed Pharmaceuticals on September 2, 2024 and sell it today you would lose (199.00) from holding InMed Pharmaceuticals or give up 31.69% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Allarity Therapeutics  vs.  InMed Pharmaceuticals

 Performance 
       Timeline  
Allarity Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Allarity Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's essential indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
InMed Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days InMed Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Allarity Therapeutics and InMed Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Allarity Therapeutics and InMed Pharmaceuticals

The main advantage of trading using opposite Allarity Therapeutics and InMed Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Allarity Therapeutics position performs unexpectedly, InMed Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in InMed Pharmaceuticals will offset losses from the drop in InMed Pharmaceuticals' long position.
The idea behind Allarity Therapeutics and InMed Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets